Penetration of erythromycin stearate into maxillary sinus mucosa and secretion in chronic maxillary sinusitis. 1977

M Paavolainen, and A Kohonen, and T Palva, and O V Renkonen

The penetration of oral erythromycin stearate (Abboticin), administered in a dosage of 500 mg three times a day, into the maxillary sinus mucosa and secretion was studied in 15 patients (22 sinuses) operated on for chronic maxillary sinusitis. The average concentration in serum was 2.3 microgram/ml, 1.2 microgram/ml in secretion, and 1.8 microgram/ml in mucosa. These concentrations are highly effective against diplococci and most aerobic and anaerobic streptococci (MIC value 0.06 microgram/ml) but not against Haemophilus influenzae (MIC value for 80% of 2 microgram/ml).

UI MeSH Term Description Entries
D008443 Maxillary Sinus The air space located in the body of the MAXILLARY BONE near each cheek. Each maxillary sinus communicates with the middle passage (meatus) of the NASAL CAVITY on the same side. Antrum of Highmore,Maxillary Antrum,Maxillary Ostium,Antrum, Maxillary,Highmore Antrum,Maxillary Antrums,Maxillary Ostiums,Sinus, Maxillary
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009297 Nasal Mucosa The mucous lining of the NASAL CAVITY, including lining of the nostril (vestibule) and the OLFACTORY MUCOSA. Nasal mucosa consists of ciliated cells, GOBLET CELLS, brush cells, small granule cells, basal cells (STEM CELLS) and glands containing both mucous and serous cells. Nasal Epithelium,Schneiderian Membrane,Epithelium, Nasal,Membrane, Schneiderian,Mucosa, Nasal
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004917 Erythromycin A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erycette,Erymax,Erythromycin A,Erythromycin C,Erythromycin Lactate,Erythromycin Phosphate,Ilotycin,T-Stat,Lactate, Erythromycin,Phosphate, Erythromycin,T Stat,TStat
D006193 Haemophilus influenzae A species of HAEMOPHILUS found on the mucous membranes of humans and a variety of animals. The species is further divided into biotypes I through VIII. Bacterium influenzae,Coccobacillus pfeifferi,Haemophilus meningitidis,Hemophilus influenzae,Influenza-bacillus,Mycobacterium influenzae
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

M Paavolainen, and A Kohonen, and T Palva, and O V Renkonen
January 1975, Scandinavian journal of infectious diseases,
M Paavolainen, and A Kohonen, and T Palva, and O V Renkonen
January 1991, Acta oto-laryngologica,
M Paavolainen, and A Kohonen, and T Palva, and O V Renkonen
January 1983, Chemotherapy,
M Paavolainen, and A Kohonen, and T Palva, and O V Renkonen
January 1975, Acta oto-laryngologica,
M Paavolainen, and A Kohonen, and T Palva, and O V Renkonen
October 1988, The Journal of antimicrobial chemotherapy,
M Paavolainen, and A Kohonen, and T Palva, and O V Renkonen
September 2000, Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology,
M Paavolainen, and A Kohonen, and T Palva, and O V Renkonen
January 1978, Scandinavian journal of infectious diseases. Supplementum,
M Paavolainen, and A Kohonen, and T Palva, and O V Renkonen
April 2020, Laryngoscope investigative otolaryngology,
M Paavolainen, and A Kohonen, and T Palva, and O V Renkonen
July 1989, Journal of chemotherapy (Florence, Italy),
M Paavolainen, and A Kohonen, and T Palva, and O V Renkonen
September 2005, International journal of pediatric otorhinolaryngology,
Copied contents to your clipboard!